Samsung Biologics provides contract development and manufacturing organization (CDMO) services for biopharmaceuticals, including development, manufacturing, and quality services, self-described as a leading global CDMO.

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.

COM:SAMSUNGBIOLOGICS

Samsung Biologics

Last Close

938K

21/11 06:30

Market Cap

58.01T

Beta: -

Volume Today

130.86K

Avg: -

locale

market

industry

website

ipo date

peer of

competitor of

Metrics